Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych TopicsConsultation-liaison psychiatry

Psych · Consultation-liaison psychiatry

Parkinson disease psychiatry

Also known as Parkinson's disease psychosis · PD psychosis · Impulse control disorders Parkinson · Dopamine dysregulation syndrome · Parkinson disease depression · Neuropsychiatric Parkinson disease · Pimavanserin · Clozapine Parkinson psychosis

Exam-exhaustive fellowship topic on the psychiatry of Parkinson disease: depression and apathy, PD psychosis (Ravina criteria, visual hallucinations), clozapine and pimavanserin, impulse control disorders from dopamine agonists, dopamine dysregulation syndrome, cognitive spectrum, and joint CL–neurology management. FRANZCP-primary, globally tagged.

high16 referencesUpdated 26 July 202613 min readVerification in progress

Practise this topic

  • 10 MCQs

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

  • New visual hallucinations or paranoid jealousy in PD — treat as PD psychosis spectrum; exclude delirium first
  • Never use high-potency D2 blockers (haloperidol, typical antipsychotics; risperidone/olanzapine traps) for PD psychosis — risk of severe motor worsening
  • Pathological gambling, hypersexuality, binge eating, or compulsive shopping after dopamine agonist start — reduce/stop the agonist with neurology
  • Compulsive extra levodopa use, severe dyskinesias, and craving — dopamine dysregulation syndrome, not simple non-adherence
  • Acute fluctuation with fever or infection — delirium until proven otherwise, not 'just PD psychosis'
  • Starting clozapine without FBC monitoring pathway and very low starting dose is unsafe
  • Untreated depression and suicide risk in PD are not 'understandable demoralisation' only
On this page
Study tools

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

FRANZCPMRCPsychABPNMD-DNBNEET-SS

Red flags

  • New visual hallucinations or paranoid jealousy in PD — treat as PD psychosis spectrum; exclude delirium first
  • Never use high-potency D2 blockers (haloperidol, typical antipsychotics; risperidone/olanzapine traps) for PD psychosis — risk of severe motor worsening
  • Pathological gambling, hypersexuality, binge eating, or compulsive shopping after dopamine agonist start — reduce/stop the agonist with neurology
  • Compulsive extra levodopa use, severe dyskinesias, and craving — dopamine dysregulation syndrome, not simple non-adherence
  • Acute fluctuation with fever or infection — delirium until proven otherwise, not 'just PD psychosis'
  • Starting clozapine without FBC monitoring pathway and very low starting dose is unsafe
  • Untreated depression and suicide risk in PD are not 'understandable demoralisation' only
The one-line answer

Parkinson disease psychiatry is core CL work: treat depression actively (SAD-PD-supported antidepressants plus CBT, never dismiss it as demoralisation), recognise PD psychosis on the Ravina spectrum and manage it with DRT simplification then low-dose clozapine or pimavanserin — never a high-potency D2 blocker — and hunt impulse control disorders and dopamine dysregulation syndrome driven by dopamine agonists and excess DRT. Always co-manage with neurology.[1][4][6][8][9]

Meet the patient

A 66-year-old retired engineer with eight years of idiopathic PD is brought in by his wife. Six months ago his neurologist added pramipexole for motor control. Three months ago he started buying lottery tickets in bulk. Last night he lost the house deposit on an online gambling site. He is not psychotic, not depressed, and has no insight at all — "it's just a hobby."[4][5]

Two exam questions are now live. Is this the disease or the drug? and what do you change first? The whole topic is the answer to those two, plus the one no one should ever get wrong: which antipsychotic is forbidden in PD?[4][11][15]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References16ShowHide
  1. [1]Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group Mov Disord, 2007.PMID 17266092
  2. [2]Fénelon G, Mahieux F, Huon R, Ziégler M Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors Brain, 2000.PMID 10734005
  3. [3]Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF A systematic review of prevalence studies of depression in Parkinson's disease Mov Disord, 2008.PMID 17987654
  4. [4]Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Arch Neurol, 2010.PMID 20457959
  5. [5]Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case--control study Ann Neurol, 2011.PMID 21416496
  6. [6]Parkinson Study Group Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease N Engl J Med, 1999.PMID 10072410
  7. [7]Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up J Neurol Neurosurg Psychiatry, 2004.PMID 15090561
  8. [8]Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial Lancet, 2014.PMID 24183563
  9. [9]Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease Neurology, 2012.PMID 22496199
  10. [10]Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial Am J Psychiatry, 2011.PMID 21676990
  11. [11]Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review Mov Disord, 2019.PMID 30653247
  12. [12]Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease N Engl J Med, 2004.PMID 15590953
  13. [13]Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies J Neurol Neurosurg Psychiatry, 2000.PMID 10727476
  14. [14]O'Sullivan SS, Evans AH, Lees AJ Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management CNS Drugs, 2009.PMID 19173374
  15. [15]Weintraub D, Chiang C, Kim HM, et al. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease JAMA Neurol, 2016.PMID 26999262
  16. [16]Connolly BS, Lang AE Pharmacological treatment of Parkinson disease: a review JAMA, 2014.PMID 24756517

Test yourself

Practise what you just read

  • 10 MCQs
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousPalliative care psychiatryConsultation-liaison psychiatryNextPerinatal psychiatry in the general hospitalConsultation-liaison psychiatry